ArticleHepatology international2023

Correction to: Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.

Takeshi Hatanaka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.